Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer.
Sasha C DruskinJeffrey J TosoianAllen YoungSarah CollicaArnav SrivastavaKamyar GhabiliKatarzyna J MacuraH Ballentine CarterAlan W PartinLori J SokollAshley E RossChristian P PavlovichPublished in: BJU international (2018)
In this contemporary cohort of men undergoing prostate biopsy for the diagnosis of PCa, PHID outperformed PHI and other PSA derivatives in the diagnosis of clinically significant cancer. Incorporating age, PNB status and PI-RADS score led to even further gains in the diagnostic performance of PHID. Furthermore, PI-RADS score was found to be complementary to PHID. Using 0.44 as a threshold for PHID, 35.3% of unnecessary biopsies could have been avoided at the cost of missing 7.7% of clinically significant cancers. Despite these encouraging results, prospective validation is needed.
Keyphrases
- prostate cancer
- radical prostatectomy
- magnetic resonance imaging
- ultrasound guided
- fine needle aspiration
- healthcare
- public health
- papillary thyroid
- mental health
- computed tomography
- squamous cell carcinoma
- squamous cell
- magnetic resonance
- health information
- middle aged
- childhood cancer
- benign prostatic hyperplasia
- contrast enhanced
- climate change
- young adults
- lymph node metastasis